Ochsner Health COVID-19 SharePoint Site "Safety On Site" Click here to enter an S.O.S.
Medications listed are available on OH EPIC Formulary, unless otherwise noted.
Not all formulary medications are available at each facility. Please refer to your local pharmacy for available inventory.
Search results for:

hyaluronidase-nivolumab

hyaluronidase-nivolumab
Drug Name Form Strength Infusion Center Available Restricted Non-formulary Ambulatory Available Interchange REMS
Opdivo Qvantig SOLUTION, SUBCUTANEOUS nvhy 10,000 units-600 mg/5 mL        
VIEW MORE Antineoplastic Agents
CLASS
100000
Additional Information and Links

OH Epic Formulary, available as an option to switch patients to.

Restricted to:

  • Indication: Current FDA-approved indications for the treatment of:
    • Renal Cell Carcinoma (RCC)
    • Melanoma
    • Non-Small Cell Lung Cancer (NSCLC)
    • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    • Urothelial Carcinoma (UC)
    • Colorectal Cancer
    • Hepatocellular Carcinoma (HCC)
    • Esophageal Cancer
    • Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma
  • Service line: Hematology/Oncology
  • Formulary location: Outpatient 
  • Service location: Outpatient Infusion, Home Infusion
  • Patient population: Adults (≥ 18 years
  • Prior authorization required: Yes
  • Restriction/criteria of use (all will apply unless specified):
    • For use across all previously FDA- approved adult solid tumor indications of nivolumab (Opdivo) IV (except for use in combination with ipilimumab).
    • Not to use in combination use with ipilimumab IV.
Last updated: Jun. 12, 2025

This site is intended for the staff of Ochsner Health. While others may view accessible pages, Ochsner Health makes no warranty, express or implied, as to the use of this information outside of Ochsner Health.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved